查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1139830

醫療保健CMO的全球市場:各類型(醫藥品，醫療設備)，各地區(北美，歐洲，亞太地區，全球其他地區)分析，規模和趨勢，COVID-19影響與至2027年的預測

Global Healthcare CMO Market: Analysis By Type (Pharmaceutical and Medical Device), By Region (North America, Europe, Asia Pacific, ROW), Size and Trends with Impact of COVID-19 and Forecast up to 2027
出版日期: | 出版商: Daedal Research | 英文 140 Pages | 訂單完成後即時交付

價格

全球醫療保健CMO的市場規模，從2021年的1,159億美元，預計2027年達到2,302億4,000萬美元，從2022年到2027年的預測期間內以12.12％的年複合成長率成長。

本報告提供全球醫療保健CMO市場相關調查分析，市場分析，市場動態，競爭情形等系統性資訊。

目錄

第1章 摘要整理

第2章 簡介

  • 醫療保健CMO:概要
    • 醫療保健CMO的優點
  • 醫療保健CMO市場區隔:概要
    • 醫療保健CMO市場區隔

第3章 全球市場分析

  • 全球醫療保健CMO市場:分析
    • 全球醫療保健CMO市場:概要
    • 全球醫療保健CMO市場:各金額
    • 全球醫療保健CMO市場(醫藥品，醫療設備):各類型
    • 全球醫療保健CMO市場(北美，歐洲，亞太地區，全球其他地區):各地區
  • 全球醫療保健CMO市場:類型分析
    • 全球醫療保健CMO市場:概要:各類型
    • 全球醫藥品CMO市場:各金額
    • 全球醫藥品CMO市場(醫藥品有效成分(API)，其他):各類服務
    • 全球醫藥品CMO市場:概要:各類服務
    • 全球醫藥品有效成分(API)CMO市場:各金額
    • 全球及其他的醫藥品CMO市場:各金額
    • 全球醫療設備CMO市場:各金額

第4章 地區市場分析

  • 北美的醫療保健CMO市場:分析
    • 北美的醫療保健CMO市場:概要
    • 北美的醫療保健CMO市場:各金額
    • 北美的醫療保健CMO市場(美國，加拿大，墨西哥):各地區
    • 美國的醫療保健CMO市場:各金額
    • 美國的醫療保健CMO市場(醫藥品，醫療設備):各類型
    • 美國的醫藥品醫療保健CMO市場:各金額
    • 美國的醫療設備醫療保健CMO市場:各金額
    • 加拿大的醫療保健CMO市場:各金額
    • 墨西哥的醫療保健CMO市場:各金額
  • 歐洲的醫療保健CMO市場:分析
    • 歐洲的醫療保健CMO市場:概要
    • 歐洲的醫療保健CMO市場:各金額
    • 歐洲的醫療保健CMO市場(德國，英國，法國，義大利，西班牙，其他的歐洲):各地區
    • 德國的醫療保健CMO市場:各金額
    • 英國的醫療保健CMO市場:各金額
    • 法國的醫療保健CMO市場:各金額
    • 義大利的醫療保健CMO市場:各金額
    • 西班牙的醫療保健CMO市場:各金額
    • 其他的歐洲的醫療保健CMO市場:各金額
  • 亞太地區的醫療保健CMO市場:分析
    • 亞太地區的醫療保健CMO市場:概要
    • 亞太地區的醫療保健CMO市場:各金額
    • 亞太地區的醫療保健CMO市場(中國，日本，印度，韓國，其他的亞太地區):各地區
    • 中國的醫療保健CMO市場:各金額
    • 日本的醫療保健CMO市場:各金額
    • 印度的醫療保健CMO市場:各金額
    • 韓國的醫療保健CMO市場:各金額
    • 其他的亞太地區的醫療保健CMO市場:各金額
  • 全球其他地區的醫療保健CMO市場:分析
    • 全球其他地區的醫療保健CMO市場:概要
    • 全球其他地區的醫療保健CMO市場:各金額

第5章 COVID-19影響

  • 對醫藥品受託製造的契約的劇增
  • 在醫藥品受託製造的需求劇增中的供應鏈問題
  • 供應鏈中斷時的準備
  • COVID-19後設想情境

第6章 市場動態

  • 促進因素
    • 老年人口的劇增
    • 醫療保健費增加
    • 慢性疾病的擴大增加
    • 學名藥的需求高漲
    • 對藥草產品的傾倒的高漲
    • 對醫藥品有效成分(API)的需求增加
  • 課題
    • 迅速的技術進步
    • 專利，著作權，商標，企業秘密的依賴
  • 市場趨勢
    • 人工智慧技術的作用增加
    • 高度的呼吸設備的演進

第7章 競爭情形

  • 全球醫療保健CMO市場企業的財務比較
  • 全球醫療保健CMO市場企業:各研究開發(R&D)費用

第8章 企業簡介

  • Catalent Pharma Solutions Inc.
  • Samsung Biologics Co. Ltd.
  • Aurobindo Pharma Limited
  • Boehringher Ingelheim
  • Integer Holdings Corporation
  • Piramal Enterprises Limited
  • Lonza Group AG
  • Koninklijke DSM N.V. (Royal DSM)
  • Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Fareva Group
  • Symbiosis Pharmaceutical Services

The global healthcare CMO market was valued at US$115.90 billion in 2021, and is predicted to grow to US$230.24 billion in 2027. Healthcare CMOs, or healthcare contract manufacturing organizations, are companies that provide comprehensive services such as drug development and manufacturing for a set period of time under a legal contract.

In the healthcare industry, a Contract Manufacturing Organization (CMO) provides services to pharmaceutical companies, hospitals, and others. Pre-formulation, formulation development, stability studies, method development, pre-clinical and Phase I clinical trial materials, and late-stage clinical trial materials are among the services provided. The global healthcare CMO market is determined to grow at a CAGR of 12.12% over the forecasted period of 2022-2027.

Market Segmentation Analysis:

By Type: The report identifies two segments on the basis of type: Pharmaceutical and Medical Device. Pharmaceutical CMO segment is further divided into two segment on the basis of service: Active Pharmaceutical Ingredients (API) and Others. The device manufacturing segment is expected to grow at the fastest rate in the market during the forecast period, with a CAGR of 13%, owing to increasing outsourcing of device manufacturing due to a lack of in-house manufacturing facilities and complexity. CMOs have quality management systems, assembly, integration and testing capabilities besides supply chain management, experienced manufacturers have systems in place to quickly partner with health care organizations during the fotrecasted period.

By Region: In the report, the global healthcare CMO market is divided into four regions: North America, Europe, Asia Pacific, and ROW. North America accounted for the maximum share of more than 37% of the global market in 2021. The market in North America is being driven by the region's increased emphasis on drug discovery and manufacturing outsourcing. The region is increasing its use of scientific exploration of disease mechanisms leading to the discovery and development of agents. Pre-clinical testing is an important stage in pharmaceutical research. At this stage, several tests are performed to determine whether a drug is ready for clinical trials.

Asia Pacific is predicted to grow at a significantly high rate during the forecasted period. The governments in various countries in this region are placing large contracts with local CMOs to speed up the production of life supporting devices like ventilators to counter the COVID-19 pandemic. Medical devices like ventilator therefore become more important for providing life support to patients. Therefore, collaboration of authorities with CMOs would lead to increase in production of ventilators, this would bolster the growth of the market during the forecasted years.

Market Dynamics:

Growth Drivers: One of the key drivers of the market's expansion is the growing inclination towards herbal products. Consumers have recently expressed a strong preference for natural/herbal beauty products, so herbal ingredients are increasingly being used in cosmetics and personal care products. In addition, companies are putting more effort into switching from synthetic chemicals to natural ingredients, primarily in response to growing consumer demand and in an effort to find a sustainable source of raw materials. To meet this ongoing demand, organizations are shifting their manufacturing processes to third-party CMOs, which aids in the growth of CMOs in the cosmetics and personal care sector, thus boosting the market growth. Other significant growth factors of the market include, surging geriatric population, rising healthcare expenditure, increasing spread of chronic diseases, escalating demand for generic drugs, and increasing demand for API.

Challenges: However, some challenges are impeding the growth of the market such as rapid technological advancement and dependent on patents, copyrights, trademarks and trade secrets. Industry players rely on a combination of know-how, trade secrets, patents, copyrights, trademarks, and other intellectual property laws, nondisclosure and other contractual provisions, and technical measures to protect many of company's offerings and intangible assets. These proprietary rights are important to the ongoing operations. The company's exclusive rights under certain of the offerings are protected by patents, some of which would expire in the near term. When patents covering an offering expire, loss of exclusivity may occur, which may force companies to compete with third parties, thereby negatively affecting the revenue and profitability and simultaneously hinders the growth of the industry.

Trends: The market is projected to grow at a fast pace during the forecast period, due to escalating role of artificial intelligence technology and evolution of advanced respiratory equipment. Healthcare artificial intelligence (AI) has transformed by assisting in repetitive tasks, designing treatment plans, medication management, and drug discovery. It can also be effectively used for healthcare data management by collecting, storing, and normalizing the data. Contract manufacturers are incorporating AI and other technological innovations to become more cost-effective and speed up production time. In addition, pharmaceutical CMOs are constantly developing AI technology in order to facilitate better risk detection and, in turn, improve the quality and safety of pharmaceutical products.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic has become a major public health concern around the world. However, the market experienced a positive demand shock, attributable to the increasing number of biopharmaceutical services provided to CMOs. CMOs have been investing in and acquiring facilities in order to be ready for high-volume production units. This pandemic has proven to be an era of exponential growth in facility and bioprocessing units to have a higher output for increased and continuous supply.

Vaccine development and manufacturing activity in the healthcare CMO market has increased in the last year, owing primarily to the industry's response to the COVID-19 pandemic. This expansion is expected to continue in the coming years as well. CMOs have made capacity and resource investments to address supply chain challenges. The CMO industry has seen an increase in modular construction and expansion, investments in cutting-edge technology, and process intensification strategies. Furthermore, many CMOs are expanding their capabilities in new modalities such as [messenger RNA] mRNA and cell and gene therapy, which would drive the growth of the market during the post COVID period.

Competitive Landscape:

Global healthcare CMO market is moderately consolidated. Strategic collaborations are another common strategy used to gain a competitive advantage. For example, Catalent entered into an agreement with Zumutor Biologics Inc., in February 2020, to produce Zumutor's ZM008 to treat solid tumours.

The key players in the global healthcare CMO market are:

Catalent Pharma Solutions, Inc.

Samsung Biologics Co. Ltd.

Aurobindo Pharma Limited

Boehringer Ingelheim GmbH

Integer Holdings Corporation

Piramal Enterprises Limited

Lonza Group AG

Koninklijke DSM N.V. (Royal DSM)

Thermo Fisher Scientific Inc.

Recipharm AB

Fareva Group

Symbiosis Pharmaceutical Services

The key players in the healthcare CMO market provides a detailed competitive landscape and focus on launching novel products with the necessary approvals. There is a continuing need for research and development, which is still a key strategy among market players. These major players have been implementing novel strategies to expand market prospects in the coming years. In April 2021, Thermo Fisher Scientific announced the acquisition of PPD, Inc., global provider of pharmaceutical manufacturing and clinical research services to the biotech industry. This would improve the company's market position by increasing their manufacturing capacity and customer base. In May 2021, Samsung Biologics and Moderna Inc. announced a collaboration to provide fill and finish services for Moderna's COVID-19 Vaccine. 

Table of Contents

    1. Executive Summary

    2. Introduction

    • 2.1 Healthcare Contract Manufacturing Organization (CMO): An Overview
      • 2.1.1 Benefits Of Healthcare CMOs
    • 2.2 Healthcare CMO Segmentation: An Overview
      • 2.2.1 Healthcare CMO Segmentation

    3. Global Market Analysis

    • 3.1 Global Healthcare Contract Manufacturing Organization (CMO) Market: An Analysis
      • 3.1.1 Global Healthcare CMO Market: An Overview
      • 3.1.2 Global Healthcare Contract Manufacturing Organization (CMO) Market by Value
      • 3.1.3 Global Healthcare Contract Manufacturing Organization (CMO) Market by Type (Pharmaceutical and Medical Device)
      • 3.1.4 Global Healthcare Contract Manufacturing Organization (CMO) Market by Region (North America, Europe, Asia Pacific, and rest of the World (ROW)
    • 3.2 Global Healthcare CMO Market: Type Analysis
      • 3.2.1 Global Healthcare CMO Market by Type: An Overview
      • 3.2.2 Global Pharmaceutical CMO Market by Value
      • 3.2.3 Global Pharmaceutical CMO Market by Service (Active Pharmaceutical Ingredients (API) and Others)
      • 3.2.3 Global Pharmaceutical CMO Market by Service: An Overview
      • 3.2.4 Global Active Pharmaceutical Ingredients (API) CMO Market by Value
      • 3.2.5 Global Other Pharmaceuticals CMO Market by Value
      • 3.2.6 Global Medical Devices CMO Market by Value

    4. Regional Market Analysis

    • 4.1 North America Healthcare CMO Market: An Analysis
      • 4.1.1 North America Healthcare CMO Market: An Overview
      • 4.1.2 North America Healthcare CMO Market by Value
      • 4.1.3 North America Healthcare CMO Market by Region (The US, Canada and Mexico)
      • 4.1.4 The US Healthcare CMO Market by Value
      • 4.1.5 The US Healthcare CMO Market by Type (Pharmaceutical and Medical Device)
      • 4.1.6 The US Pharmaceutical Healthcare CMO Market by Value
      • 4.1.7 The US Medical Devices Healthcare CMO Market by Value
      • 4.1.8 Canada Healthcare CMO Market by Value
      • 4.1.9 Mexico Healthcare CMO Market by Value
    • 4.2 Europe Healthcare CMO Market: An Analysis
      • 4.2.1 Europe Healthcare CMO Market: An Overview
      • 4.2.2 Europe Healthcare CMO Market by Value
      • 4.2.3 Europe Healthcare CMO Market by Region (Germany, The UK, France, Italy, Spain, and Rest of the Europe)
      • 4.2.4 Germany Healthcare CMO Market by Value
      • 4.2.5 The UK Healthcare CMO Market by Value
      • 4.2.6 France Healthcare CMO Market by Value
      • 4.2.7 Italy Healthcare CMO Market by Value
      • 4.2.8 Spain Healthcare CMO Market by Value
      • 4.2.9 Rest of Europe Healthcare CMO Market by Value
    • 4.3 Asia Pacific Healthcare CMO Market: An Analysis
      • 4.3.1 Asia Pacific Healthcare CMO Market: An Overview
      • 4.3.2 Asia Pacific Healthcare CMO Market by Value
      • 4.3.3 Asia Pacific Healthcare CMO Market by Region (China, Japan, India, South Korea, and Rest of the Asia Pacific)
      • 4.3.4 China Healthcare CMO Market by Value
      • 4.3.5 Japan Healthcare CMO Market by Value
      • 4.3.6 India Healthcare CMO Market by Value
      • 4.3.7 South Korea Healthcare CMO Market by Value
      • 4.3.8 Rest of Asia Pacific Healthcare CMO Market by Value
    • 4.4 Rest of World Healthcare CMO Market: An Analysis
      • 4.4.1 Rest of World Healthcare CMO Market: An Overview
      • 4.4.2 Rest of World Healthcare CMO Market by Value

    5. Impact of Covid-19

    • 5.1 Surge in Contracts to CDMOs
    • 5.2 Supply Chain Issues Amidst Surge in Demand for CDMOs
    • 5.3 Preparedness Measures in the Event of Supply Chain Disruption
    • 5.4 Post-COVID Scenario

    6. Market Dynamics

    • 6.1 Growth Drivers
      • 6.1.1 Surging Geriatric Population
      • 6.1.2 Rising Healthcare Expenditure
      • 6.1.3 Increasing Spread of Chronic Diseases
      • 6.1.4 Escalating Demand for Generic Drugs
      • 6.1.5 Growing Inclination Towards Herbal Products
      • 6.1.6 Increasing Demand for Active Pharmaceutical Ingredient (API)
    • 6.2 Challenges
      • 6.2.1 Rapid Technological Advancements
      • 6.2.2 Dependent on Patents, Copyrights, Trademarks and Trade Secrets
    • 6.3 Market Trends
      • 6.3.1 Escalating Role of Artificial Intelligence Technology
      • 6.3.2 Evolution of Advanced Respiratory Equipment

    7. Competitive Landscape

    • 7.1 Global Healthcare CMO Market Players Financial Comparison
    • 7.2 Global Healthcare CMO Market Players by Research & Development (R&D) Expenses

    8. Company Profiles

    • 8.1 Catalent Pharma Solutions Inc.
      • 8.1.1 Business Overview
      • 8.1.2 Operating Segments
      • 8.1.3 Business Strategy
    • 8.2 Samsung Biologics Co. Ltd.
      • 8.2.1 Business Overview
      • 8.2.2 Operating Segments
      • 8.2.3 Business Strategy
    • 8.3 Aurobindo Pharma Limited
      • 8.3.1 Business Overview
      • 8.3.2 Operating Segments
      • 8.3.3 Business Strategy
    • 8.4 Boehringher Ingelheim
      • 8.4.1 Business Overview
      • 8.4.2 Operating Segments
      • 8.4.3 Business Strategy
    • 8.5 Integer Holdings Corporation
      • 8.5.1 Business Overview
      • 8.5.2 Operating Segments
      • 8.5.3 Business Strategy
    • 8.6 Piramal Enterprises Limited
      • 8.6.1 Business Overview
      • 8.6.2 Operating Segments
      • 8.6.3 Business Strategy
    • 8.7 Lonza Group AG
      • 8.7.1 Business Overview
      • 8.7.2 Operating Segments
      • 8.7.3 Business Strategy
    • 8.8 Koninklijke DSM N.V. (Royal DSM)
      • 8.8.1 Business Overview
      • 8.8.2 Operating Segments
      • 8.8.3 Business Strategy
    • 8.9 Thermo Fisher Scientific Inc.
      • 8.9.1 Business Overview
      • 8.9.2 Operating Segments
      • 8.9.3 Business Strategy
    • 8.10 Recipharm AB
      • 8.10.1 Business Overview
      • 8.10.2 Business Strategy
    • 8.11 Fareva Group
      • 8.11.1 Business Overview
      • 8.11.2 Business Strategy
    • 8.12 Symbiosis Pharmaceutical Services
      • 8.12.1 Business Overview
      • 8.12.2 Business Strategy

List of Tables

  • Table 1: Contracts Placed with Pharmaceutical CDMOs; 2020
  • Table 2: Global Healthcare CMO Market Players Financial Comparison; 2021

List of Figures

  • Figure 1: Benefits Of Healthcare CMOs
  • Figure 2: Healthcare CMO Segmentation
  • Figure 3: Global Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 4: Global Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 5: Global Healthcare CMO Market by Type; 2021 (Percentage, %)
  • Figure 6: Global Healthcare CMO Market by Region; 2021 (Percentage, %)
  • Figure 7: Global Pharmaceutical CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 8: Global Pharmaceutical CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 9: Global Pharmaceutical CMO Market by Service; 2021 (Percentage, %)
  • Figure 10: Global Active Pharmaceutical Ingredients (API) CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 11: Global Active Pharmaceutical Ingredients (API) CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 12: Global Other Pharmaceuticals CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 13: Global Other Pharmaceuticals CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 14: Global Medical Devices CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 15: Global Medical Devices CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 16: North America Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 17: North America Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 18: North America Healthcare CMO Market by Region; 2021 (Percentage, %)
  • Figure 19: The US Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 20: The US Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 21: The US Healthcare CMO Market by Type; 2021 (Percentage, %)
  • Figure 22: The US Pharmaceutical Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 23: The US Pharmaceutical Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 24: The US Medical Devices Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 25: The US Medical Devices Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 26: Canada Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 27: Canada Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 28: Mexico Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 29: Mexico Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 30: Europe Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 31: Europe Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 32: Europe Healthcare CMO Market by Region; 2021 (Percentage, %)
  • Figure 33: Germany Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 34: Germany Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 35: The UK Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 36: The UK Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 37: France Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 38: France Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 39: Italy Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 40: Italy Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 41: Spain Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 42: Spain Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 43: Rest of Europe Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 44: Rest of Europe Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 45: Asia Pacific Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 46: Asia Pacific Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 47: Asia Pacific Healthcare CMO Market by Region; 2021 (Percentage, %)
  • Figure 48: China Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 49: China Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 50: Japan Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 51: Japan Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 52: India Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 53: India Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 54: South Korea Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 55: South Korea Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 56: Rest of Asia Pacific Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 57: Rest of Asia Pacific Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 58: Rest of World Healthcare CMO Market by Value; 2017-2021 (US$ Billion)
  • Figure 59: Rest of World Healthcare CMO Market by Value; 2022-2027 (US$ Billion)
  • Figure 60: Global Population Proportion Above 65 Years of Age; 2019 & 2030 (Million)
  • Figure 61: Global Healthcare Expenditure; 2017 & 2022 (US$ Trillion)
  • Figure 62: Global Chronic Disease Growth; 2016-2025 (Percentage, %)
  • Figure 63: Global Generic Drugs Market Value, 2020-2025 (US$ Billion)
  • Figure 64: Global Natural And Organic Cosmetics And Personal Care Market Value, 2021-2027 (US$ Billion)
  • Figure 65: Global Healthcare Artificial Intelligence Market Value; 2020-2025 (US$ Billion)
  • Figure 66: The Global Healthcare CMO Market Players by Research & Development (R&D) Expenses; 2020 & 2021 (US$ Million)
  • Figure 67: Catalent, Inc. Net Revenue by Segments; 2021 (Percentage, %)
  • Figure 68: Samsung Biologics Co. Ltd. Revenue by Product Type; 2021 (Percentage, %)
  • Figure 69: Aurobindo Pharma Limited Revenue by Business Segments; 2021 (Percentage, %)
  • Figure 70: Boehringher Ingelheim Net Sales by Segments; 2021 (Percentage, %)
  • Figure 71: Integer Holdings Corporation Net Sales by Segments; 2021 (Percentage, %)
  • Figure 72: Piramal Enterprises Limited Net Sales by Business; 2021 (Percentage, %)
  • Figure 73: Lonza Group AG Sales by Segments; 2021 (Percentage, %)
  • Figure 74: Koninklijke DSM N.V. Net Sales by Business Segments; 2021 (Percentage, %)
  • Figure 75: Thermo Fisher Scientific Inc. Revenues by Segments; 2021 (Percentage, %)